Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

[1]  Andrea Benedetti,et al.  Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes , 2017, Systematic Reviews.

[2]  V. Cook,et al.  Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada , 2017, BMC Infectious Diseases.

[3]  H. Schünemann,et al.  World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update , 2017, European Respiratory Journal.

[4]  Zhiyi Lan,et al.  An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis , 2017, European Respiratory Journal.

[5]  A. Benedetti,et al.  Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. , 2017, The Lancet. Infectious diseases.

[6]  H. S. Schaaf,et al.  Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  H. Park,et al.  Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis , 2015, Antimicrobial Agents and Chemotherapy.

[8]  Jae Ho Lee,et al.  Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome , 2015, Antimicrobial Agents and Chemotherapy.

[9]  D. Menzies,et al.  Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment , 2015, European Respiratory Journal.

[10]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[11]  T. Clark,et al.  Recurrence due to Relapse or Reinfection With Mycobacterium tuberculosis: A Whole-Genome Sequencing Approach in a Large, Population-Based Cohort With a High HIV Infection Prevalence and Active Follow-up , 2014, The Journal of infectious diseases.

[12]  C. Hamilton,et al.  Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  S. Rüsch-Gerdes,et al.  Occurrence of rpoB Mutations in Isoniazid-Resistant but Rifampin-Susceptible Mycobacterium tuberculosis Isolates from Germany , 2013, Antimicrobial Agents and Chemotherapy.

[14]  Dick van Soolingen,et al.  Epidemiology of Isoniazid Resistance Mutations and Their Effect on Tuberculosis Treatment Outcomes , 2013, Antimicrobial Agents and Chemotherapy.

[15]  T. Cohen,et al.  Isoniazid-resistant Tuberculosis in Children: A Systematic Review , 2013, The Pediatric infectious disease journal.

[16]  R. Mckean-Cowdin,et al.  Can mycobacterial katG genetic changes in isoniazid-resistant tuberculosis influence human disease features? , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  N. Selvakumar,et al.  Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions. , 2012, The National medical journal of India.

[18]  T. Cohen,et al.  Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[19]  S. Swaminathan,et al.  Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Checchi,et al.  Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection , 2011, PloS one.

[21]  T. Victor,et al.  Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[23]  Ruth McNerney,et al.  Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala, Uganda: A Prospective Cohort Study , 2011, PLoS medicine.

[24]  T. Yoshiyama,et al.  Risk of relapse and failure after retreatment with the Category II regimen in Nepal. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  V. Thomsen,et al.  Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. , 2010, The Journal of infection.

[26]  S. Swaminathan,et al.  Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. , 2010, American journal of respiratory and critical care medicine.

[27]  M. Mirsaeidi,et al.  Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis. , 2009, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[28]  A. Benedetti,et al.  Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.

[29]  Raymund B. Dantes,et al.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[31]  Stefan Niemann,et al.  Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance , 2006, PLoS medicine.

[32]  A. Ohkado,et al.  Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[33]  W. Koh,et al.  Treatment of Isoniazid-Resistant Pulmonary Tuberculosis , 2004, Tuberculosis and respiratory diseases.

[34]  D. van Soolingen,et al.  Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  D. Menzies,et al.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[36]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[37]  J. Musser,et al.  Treatment of isoniazid-resistant tuberculosis in southeastern Texas. , 2001, Chest.

[38]  R. Prabhakar,et al.  A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. , 1997 .

[39]  J. Chien,et al.  Treatment outcome of patients with isoniazid mono-resistant tuberculosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[40]  B. D. de Jong,et al.  A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.

[41]  M. Munang,et al.  Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999-2010. , 2015, QJM : monthly journal of the Association of Physicians.

[42]  F. Cobelens,et al.  Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[43]  L. Soto-Ramírez,et al.  [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.